George B.  Abercrombie net worth and biography

George Abercrombie Biography and Net Worth

George B. Abercrombie serves as Independent Director of the Company. Mr. Abercrombie was appointed to the Board in October 2011. Mr. Abercrombie has over 30 years of experience as a business leader in the pharmaceutical industry. Mr. Abercrombie held the position of Senior Vice President and Chief Commercial Officer at Innoviva, Inc., a publicly traded bio-pharmaceutical asset management company, from 2014 to 2018. He served from 2001 to 2009 as the President and Chief Executive Officer of Hoffmann-La Roche Inc., a pharmaceutical company, where he was responsible leading operations in both the U.S. and Canada. During his tenure, Mr. Abercrombie also served as a member of the Roche Pharmaceutical Executive Committee, which was responsible for developing and implementing global strategy for the Pharmaceuticals Division. In 1993, Mr. Abercrombie joined Glaxo Wellcome Inc. as Vice President and General Manager of the Glaxo Pharmaceuticals Division, and was later promoted to Senior Vice President, U.S. Commercial Operations. Prior to joining Glaxo, he spent over ten years at Merck & Co., Inc., where he gained experience in sales and marketing, executive sales management and business development. Mr. Abercrombie began his career as a pharmacist after receiving a bachelor’s degree in pharmacy from the University of North Carolina at Chapel Hill, and later earned an MBA from Harvard University. Mr. Abercrombie also serves on the Board of Brickell Biotech, a private pharmaceutical company. He formerly served on the Boards of Directors of Inspire Pharmaceuticals, Inc., Ziopharm Oncology, Inc, Tranzyme Pharma, Aptus Health, Inc. and DemeRX. Additionally, he is an Adjunct Professor at Duke University’s Fuqua School of Business and a board member of the North Carolina GlaxoSmithKline Foundation. He previously served on the Executive Committee and Board of Directors of the Pharmaceutical Research & Manufacturers of America (PhRMA), as well as on the Board of the Johns Hopkins School of Hygiene and Pub.

What is George B. Abercrombie's net worth?

The estimated net worth of George B. Abercrombie is at least $55,005.23 as of May 24th, 2021. Mr. Abercrombie owns 9,667 shares of BioCryst Pharmaceuticals stock worth more than $55,005 as of December 10th. This net worth approximation does not reflect any other investments that Mr. Abercrombie may own. Learn More about George B. Abercrombie's net worth.

How do I contact George B. Abercrombie?

The corporate mailing address for Mr. Abercrombie and other BioCryst Pharmaceuticals executives is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. BioCryst Pharmaceuticals can also be reached via phone at (919) 859-1302 and via email at [email protected]. Learn More on George B. Abercrombie's contact information.

Has George B. Abercrombie been buying or selling shares of BioCryst Pharmaceuticals?

George B. Abercrombie has not been actively trading shares of BioCryst Pharmaceuticals during the last ninety days. Most recently, George B. Abercrombie sold 5,000 shares of the business's stock in a transaction on Tuesday, February 15th. The shares were sold at an average price of $18.50, for a transaction totalling $92,500.00. Learn More on George B. Abercrombie's trading history.

Who are BioCryst Pharmaceuticals' active insiders?

BioCryst Pharmaceuticals' insider roster includes George Abercrombie (Director), Yarlagadda Babu (Insider), Alane Barnes (Insider), Anthony Doyle (CFO), Nancy Hutson (Director), Vincent Milano (Director), William Sheridan (Insider), and Jon Stonehouse (CEO). Learn More on BioCryst Pharmaceuticals' active insiders.

Are insiders buying or selling shares of BioCryst Pharmaceuticals?

During the last twelve months, insiders at the biotechnology company sold shares 6 times. They sold a total of 127,370 shares worth more than $1,324,621.75. The most recent insider tranaction occured on June, 15th when Director Machelle Sanders sold 4,000 shares worth more than $31,920.00. Insiders at BioCryst Pharmaceuticals own 4.4% of the company. Learn More about insider trades at BioCryst Pharmaceuticals.

Information on this page was last updated on 6/15/2023.

George B. Abercrombie Insider Trading History at BioCryst Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2022Sell5,000$18.50$92,500.00View SEC Filing Icon  
11/15/2021Sell5,000$12.27$61,350.00View SEC Filing Icon  
9/10/2021Sell74,000$15.09$1,116,660.00View SEC Filing Icon  
7/15/2021Sell5,000$15.69$78,450.008,000View SEC Filing Icon  
5/24/2021Sell6,667$13.90$92,671.309,667View SEC Filing Icon  
5/10/2021Sell7,000$12.70$88,900.003,000View SEC Filing Icon  
3/5/2013Buy3,000$1.23$3,690.00View SEC Filing Icon  
See Full Table

George B. Abercrombie Buying and Selling Activity at BioCryst Pharmaceuticals

This chart shows George B Abercrombie's buying and selling at BioCryst Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioCryst Pharmaceuticals Company Overview

BioCryst Pharmaceuticals logo
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $5.69
Low: $5.59
High: $5.82

50 Day Range

MA: $5.73
Low: $4.98
High: $6.77

2 Week Range

Now: $5.69
Low: $4.82
High: $12.07


5,120,367 shs

Average Volume

3,669,082 shs

Market Capitalization

$1.17 billion

P/E Ratio


Dividend Yield